Kimura, Yutaka http://orcid.org/0000-0002-0188-0586
Kawakami, Hisato
Tamura, Shigeyuki
Fujitani, Kazumasa
Matsuyama, Jin
Imamura, Hiroshi
Iijima, Shohei
Sakai, Daisuke
Kurokawa, Yukinori
Shimokawa, Toshio
Tsujinaka, Toshimasa
Furukawa, Hiroshi
Satoh, Taroh
Article History
Received: 15 March 2023
Accepted: 4 June 2023
First Online: 19 June 2023
Declarations
:
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Y. Ki. was supported by grants and personal fees from Daiichi Sankyo Co. Ltd., outside the submitted work. H. K. has received fees and research funding from Bristol-Myers Squibb Co. Ltd., Taiho pharmaceutical Co. Ltd., Eisai Co. Ltd., and Kobayashi Pharmaceutical. Co., Ltd. as well as honoraria and lecture fees from Bristol-Myers Squibb Co. Ltd., Bayer Yakuhin Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co., Ltd., Teijin Pharma Ltd., Taiho Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co. Ltd. K. F. has received honoraria and lecture fees from Taiho Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Bristol-Myers Squibb Co. Ltd., Ono Pharmaceutical Co. Ltd., and Yakult Honsha Co. Ltd., outside the submitted work. H. I. has received honoraria and lecture fees from Taiho Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical Co. Ltd. outside the submitted work. Y. Ku has received research funding from Yakult Honsha Co. Ltd. and Taiho Pharmaceutical Co. Ltd. and lecture fees from Yakult Honsha Co. Ltd., Taiho Pharmaceutical Co. Ltd., and Nippon Kayaku Co. Ltd. outside of the submitted work. T. Sa. has received fees and research funding from Bristol-Myers Squibb Co. Ltd., T Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., Daiichi-Sankyo Co. Ltd., Chugai Pharmaceutical Co. Ltd., Yakult Honsha Co. Ltd., and HUTCHMED Ltd., as well as honoraria and lecture fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and Daiichi-Sankyo Co. Ltd.. All remaining authors have declared no conflicts of interest.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. All patients provided written informed consent.